"The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked a"...
No information provided.
Read the Neo-Synephrine (phenylephrine hydrochloride ophthalmic solution) Side Effects Center for a complete guide to possible side effects
As with all other adrenergic drugs, when NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) 10 percent ophthalmic solutions or 2.5 percent ophthalmic solution is administered simultaneously with, or up to 21 days after, administration of monoamine oxidase (MAO) inhibitors, careful supervision and adjustment of dosages are required since exaggerated adrenergic effects may occur. The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants, propranolol, reserpine, guanethidine, methyldopa, and atropine-like drugs.
It has been reported that the concomitant use of NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) 10 percent ophthalmic solutions and systemic beta blockers has caused acute hypertension and, in one case, the rupture of a congenital cerebral aneurysm. NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) may potentiate the cardiovascular depressant effects of potent inhalation anesthetic agents.
Last reviewed on RxList: 5/6/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Neo-Synephrine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.